ITCC-078 Durvalumab

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-078 Durvalumab

Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies

Promotor Name : AstraZeneca

Investigator Name : Dr Darren Hargrave

Trial registered on NCT03837899